zinzibet 50 mg
egis pharmaceuticals plc, maďarsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
zinzibet 25 mg
egis pharmaceuticals plc, maďarsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
nogron 5 mg
egis pharmaceuticals plc, maďarsko - temozolomid - 44 - cytostatica
nogron 20 mg
egis pharmaceuticals plc, maďarsko - temozolomid - 44 - cytostatica
nogron 100 mg
egis pharmaceuticals plc, maďarsko - temozolomid - 44 - cytostatica
nogron 140 mg
egis pharmaceuticals plc, maďarsko - temozolomid - 44 - cytostatica
nogron 180 mg
egis pharmaceuticals plc, maďarsko - temozolomid - 44 - cytostatica
nogron 250 mg
egis pharmaceuticals plc, maďarsko - temozolomid - 44 - cytostatica
tecartus
kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymfóm, mantle-cell - antineoplastické činidlá - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).
plavix
sanofi winthrop industrie - klopidogrel hydrogénsulfát - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombotické činidlá - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevencia atherothrombotic a thromboembolic udalosti v fibrilácia fibrillationin dospelých pacientov s fibrilácia predsiení, ktorí majú aspoň jeden rizikový faktor cievnych udalosti, nie sú vhodné na liečbu s vitamínom-k antagonisty a ktorí majú nízke riziko krvácania, klopidogrel, je indikovaná v kombinácii s asa pre prevenciu atherothrombotic a thromboembolic udalosti, vrátane mŕtvica.